ADARx Pharmaceuticals closes IPO and AbbVie private placement
The San Diego biotech raised roughly $446.3 million in its Nasdaq offering alongside an $89.3 million concurrent stock purchase by AbbVie.
SEC filing
Latest
25 stories
Yesterday
Monday, September 28
Friday, September 25
AbbVie registers first-in-human Phase 1 trial for oral ABBV-1162
ADARx prices IPO at $17 per share, AbbVie to buy stake
ADARx Pharmaceuticals sold 26.25 million shares in its Nasdaq debut and will use proceeds to fund late-stage siRNA programs including a Phase 3 hereditary angioedema trial.
SEC filing
Wednesday, September 16
AbbVie registers Phase 3 trial of telisotuzumab adizutecan in NSCLC
Thursday, September 10
AbbVie sponsors new ABBV-253 solid tumor trial; collaborates on epcoritamab lymphoma study
Friday, September 4
AbbVie posts IMGN632 BPDCN results; opens NOA LIFT filler trial vs VOLIFT
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRX
The San Diego siRNA drugmaker seeks to list its three clinical-stage and two preclinical programs, backed by a $335 million AbbVie upfront payment.
SEC filing
Thursday, September 3
AbbVie closes $10.9 billion acquisition of Apogee Therapeutics, reaffirms 2026 guidance
The deal brings AbbVie the late-stage atopic dermatitis antibody zumilokibart and an asthma combination candidate, with dilution to earnings expected through 2027 before accretion begins in 2032.
SEC filing
Friday, August 28
AbbVie registers Phase 3 trial of etentamig vs Dara-CyBorD in AL amyloidosis
Tuesday, August 25
Parabilis Medicines adds oncology veteran Craig Tendler to board
The clinical-stage biopharma named Craig L. Tendler, M.D., a former Johnson & Johnson oncology leader, as a new Class II director on August 22, 2026.
SEC filing
Monday, August 24
Oruka Therapeutics names Todd Edwards as Chief Commercial Officer
Edwards, a former Arcutis and Incyte dermatology commercial leader, joined Oruka on August 24, 2026 with a base salary, bonus target, equity grants, and a signing bonus.
SEC filing
ANI Pharmaceuticals adds Henry Gosebruch to board, Shanmugam resigns directorship
The rare disease-focused drugmaker named a longtime AbbVie strategy executive to its board effective August 19, 2026, as a current director stepped down from the board while keeping his executive role.
SEC filing
Friday, August 21
AbbVie posts results from terminated emraclidine trial, opens two studies to recruitment
Thursday, August 13
AbbVie posts Crohn's OLE results; registers Phase 3 lung cancer and Phase 1 glabellar lines trials
Wednesday, August 12
Xilio gets FDA clearance for XTX501 IND, reports Q2 2026 results
The bispecific PD-1/masked IL-2 candidate is set to begin Phase 1 dosing in the second half of 2026 as Xilio's cash runway extends into early 2028.
SEC filing
Friday, August 7
AbbVie registers three new trials spanning obesity, head and neck cancer, and atopic dermatitis
Thursday, August 6
Regenxbio reports Q2 2026 results, cites Duchenne trial win and new AbbVie funds
The company raised over $200 million in July, including a $100 million AbbVie milestone, and reaffirmed 2026-2027 timelines for RGX-202, sura-vec and RGX-121.
SEC filing
AbbVie finalizes $10 billion notes sale, pro forma debt load hits $80.4 billion
New pricing details show AbbVie's nine-tranche bond sale generated $9.98 billion in gross proceeds and will push total indebtedness to about $80.4 billion.
SEC filing (2)
Ironwood raises 2026 guidance again as apraglutide trial recruits and debt is repaid
The company lifted full-year LINZESS, revenue, and EBITDA guidance for a second straight quarter while its confirmatory apraglutide trial begins enrolling patients and it retires $200 million in convertible notes.
SEC filing
Wednesday, August 5
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updates
New chief executive takes over as company narrows 2026 revenue guidance and reports progress in DM1, FSHD and Huntington's disease programs.
SEC filing
Friday, July 31
AbbVie to acquire Apogee Therapeutics, updates 2026 EPS guidance amid Q2 results
AbbVie announced a definitive deal for Apogee's immunology pipeline, adjusted its full-year adjusted EPS range, and reported a string of regulatory approvals across its portfolio.
SEC filing
AbbVie week: BOTOX oral pain results post; new CLL, myeloma, ABBV-859 trials filed
Monday, July 27
Precision BioSciences promotes CFO to COO, names new CFO effective August 1
The Board approved the executive changes on July 23, 2026, and the company announced them in a press release on July 27, 2026.
SEC filing